Biocorp Production
Market Cap
€66.2m
Last Updated
2020/06/06 07:12 UTC
Data Sources
Company Financials +
Executive Summary
Biocorp Production designs, develops, and manufactures medical devices and drug delivery systems in France.
Rewards
Risk Analysis
Snowflake Analysis
Exceptional growth potential and good value.
Share Price & News
How has Biocorp Production's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ALCOR's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-4.7%
ALCOR
-11.5%
FR Medical Equipment
8.7%
FR Market
1 Year Return
47.2%
ALCOR
42.8%
FR Medical Equipment
-2.4%
FR Market
Return vs Industry: ALCOR exceeded the French Medical Equipment industry which returned 42.8% over the past year.
Return vs Market: ALCOR exceeded the French Market which returned -2.4% over the past year.
Shareholder returns
| ALCOR | Industry | Market | |
|---|---|---|---|
| 7 Day | -4.7% | -11.5% | 8.7% |
| 30 Day | 7.4% | -1.9% | 15.9% |
| 90 Day | 26.4% | 35.6% | 1.3% |
| 1 Year | 47.2%47.2% | 42.8%42.8% | -0.7%-2.4% |
| 3 Year | 52.6%52.6% | 43.9%42.1% | 11.2%2.2% |
| 5 Year | n/a | 144.9%139.2% | 31.1%14.3% |
Price Volatility Vs. Market
How volatile is Biocorp Production's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall St
Is Biocorp Production (EPA:ALCOR) A Risky Investment?3 months ago | Simply Wall St
Does Biocorp Production's (EPA:ALCOR) Share Price Gain of 51% Match Its Business Performance?5 months ago | Simply Wall St
Does Biocorp Production (EPA:ALCOR) Have A Healthy Balance Sheet?Valuation
Is Biocorp Production undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ALCOR (€16.05) is trading below our estimate of fair value (€135.49)
Significantly Below Fair Value: ALCOR is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ALCOR is good value based on its PE Ratio (-48.8x) compared to the Medical Equipment industry average (44.3x).
PE vs Market: ALCOR is good value based on its PE Ratio (-48.8x) compared to the French market (15.4x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ALCOR's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ALCOR is overvalued based on its PB Ratio (213x) compared to the FR Medical Equipment industry average (2.7x).
Next Steps
Future Growth
How is Biocorp Production forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
48.4%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ALCOR's forecast earnings growth (48.4% per year) is above the savings rate (0.6%).
Earnings vs Market: ALCOR's earnings (48.4% per year) are forecast to grow faster than the French market (13.7% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: ALCOR's revenue (36.1% per year) is forecast to grow faster than the French market (4.1% per year).
High Growth Revenue: ALCOR's revenue (36.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ALCOR's Return on Equity is forecast to be very high in 3 years time (69%).
Next Steps
Past Performance
How has Biocorp Production performed over the past 5 years?
-2.7%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ALCOR has high quality earnings.
Growing Profit Margin: ALCOR became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: ALCOR has become profitable over the past 5 years, growing earnings by -2.7% per year.
Accelerating Growth: ALCOR has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: ALCOR has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-2%).
Return on Equity
High ROE: Whilst ALCOR's Return on Equity (308.66%) is outstanding, this metric is skewed due to their high level of debt.
Next Steps
Financial Health
How is Biocorp Production's financial position?
Financial Position Analysis
Short Term Liabilities: ALCOR's short term assets (€6.6M) exceed its short term liabilities (€4.6M).
Long Term Liabilities: ALCOR's short term assets (€6.6M) exceed its long term liabilities (€3.2M).
Debt to Equity History and Analysis
Debt Level: ALCOR's debt to equity ratio (1659.9%) is considered high.
Reducing Debt: ALCOR's debt to equity ratio has increased from 696.7% to 1659.9% over the past 5 years.
Debt Coverage: ALCOR's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: ALCOR's interest payments on its debt are well covered by EBIT (5.5x coverage).
Balance Sheet
Next Steps
Dividend
What is Biocorp Production's current dividend yield, its reliability and sustainability?
4.66%
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ALCOR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ALCOR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ALCOR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ALCOR's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ALCOR's dividend in 3 years as they are not forecast to pay a notable one for the French market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
15.4yrs
Average management tenure
CEO
Eric Dessertenne
0.50
Tenure
Mr. Eric Dessertenne serves as Chief Executive Officer at Biocorp Production since December 2019. He had been Chief Operating Officer of Biocorp Production since December 9, 2016 until December 2019. Mr. D ...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Chairman | 5.08yrs | €28.87k | 0.0049% €3.2k | |
| Chief Executing Officer | 0.50yr | no data | no data | |
| Administrative & Financial Director | 15.42yrs | no data | no data | |
| Marketing & Communication Director | no data | no data | no data | |
| Head of Software R&D | no data | no data | no data | |
| Head of Production | no data | no data | no data | |
| Head of Product R&D | no data | no data | no data | |
| Head of Quality & Regulatory Affairs | no data | no data | no data |
15.4yrs
Average Tenure
Experienced Management: ALCOR's management team is seasoned and experienced (15.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Chairman | 5.08yrs | €28.87k | 0.0049% €3.2k | |
| Independent Director | 5.08yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Director | 5.08yrs | no data | no data | |
| Director | 5.08yrs | no data | no data | |
| Director | 5.08yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
5.1yrs
Average Tenure
Experienced Board: ALCOR's board of directors are considered experienced (5.1 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Biocorp Production's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Biocorp Production
- Ticker: ALCOR
- Exchange: ENXTPA
- Founded: 2004
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: €66.245m
- Shares outstanding: 4.13m
- Website: https://biocorpsys.com
Number of Employees
Location
- Biocorp Production
- Parc Technologique
- Lavaur-la-BEchade
- Issoire
- Auvergne
- 63500
- France
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| ALCOR | ENXTPA (Euronext Paris) | Yes | Ordinary Shares | FR | EUR | Jul 2015 |
Biography
Biocorp Production designs, develops, and manufactures medical devices and drug delivery systems in France. The company provides connected medical devices, including Inspair, a smart cap to monitor inhalers and assesses the usage of the device; Mallya, a smart cap for pen injectors that captures injection data; Onejet, a motor driven disposable auto-injector, which designs to deliver viscosity products; Datapen, a motor driven pen injector; and Injay that collects essential information, such as injection completed, time and date, type of drug, batch number, and expiration date. It also offers pharmaceutical devices, such as Newguard, a safety device compatible with various sizes of needles prefilled syringes; Biopass, a reconstitution system; and closure systems. The company was founded in 2004 and is headquartered in Issoire, France.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/06/06 07:12 |
| End of Day Share Price | 2020/06/05 00:00 |
| Earnings | 2019/12/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.